|
Carcinoma of lung
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> In conclusion, metformin may potentially enhance the therapeutic effect and increase survival in type 2 DM patients with lung cancer receiving EGFR-TKI therapy.
|
31409137 |
2020 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<b>Objectives:</b> Tumor pathology examination especially epidermal growth factor receptor (<i>EGFR</i>) mutations molecular testing has been integral part of lung cancer clinical practices.
|
31555581 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due to new mutations or bypass mechanisms.
|
29967248 |
2018 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Drug resistance is a major challenge for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) treatment of lung cancer.
|
31417255 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled <i>EGFR</i>-mutant tumors prior to treatment and after progression on EGFR TKI using targeted next-generation sequencing.<b>Experimental Design:</b> Targeted next-generation sequencing was performed on 374 consecutive patients with metastatic <i>EGFR</i>-mutant lung cancer.
|
29530932 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<i>EGFR</i> rs712829, rs712830, rs2072454, and rs11543848 single nucleotide polymorphisms (SNPs) were genotyped to test for their association with lung cancer risk.
|
30011810 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<i>EGFR</i> mutations in cfDNA, both the activating mutation and <i>EGFR</i> T790M, became undetectable in most patients in the setting of clinical response and reemerged upon disease progression.<b>Conclusions:</b> ASP8273 was well tolerated and promoted antitumor activity in patients with <i>EGFR</i>-mutant lung cancer with disease progression on prior EGFR TKI therapy.<i></i>.
|
28954786 |
2017 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
- The mutation analysis of epidermal growth factor receptor (EGFR) has become a common test to guide therapeutic decision making for lung cancer.
|
28537806 |
2017 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
-The National Cancer Care Network and the combined College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines indicate that all lung adenocarcinomas (ADCs) should be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements.
|
27552093 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
343 NSCLC patients tested for EGFR mutation at a German lung cancer centre were analysed for age, gender, and smoking status as well as for the mutation status.
|
29190621 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer-derived EGFR mutations are oncogenic and are tightly associated with clinical response to the EGFR kinase inhibitors erlotinib and gefitinib.
|
16857815 |
2006 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
|
18676761 |
2008 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer with epidermal growth factor receptor (EGFR)-activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib.
|
19010923 |
2008 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer with EGFR mutations is highly sensitive to EGFR-tyrosine kinase inhibitors.
|
21681119 |
2011 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.
|
27466205 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer is the most common cause of cancer-related mortality worldwide despite diagnostic improvements and the development of targeted therapies, notably including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
|
31262325 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer is one of the most serious threats to human where 85% of lethal death caused by non-small cell lung cancer (NSCLC) induced by epidermal growth factor receptor (EGFR) mutation.
|
31745155 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor family in lung cancer and premalignancy.
|
11894009 |
2002 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.
|
15118125 |
2004 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
|
16140919 |
2005 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations occur in highly selected subpopulations of lung cancer patients: adenocarcinoma histology, never-smoker status, East Asian ethnicity and female gender.
|
16231326 |
2006 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) gene mutations are frequently detected in lung cancer, especially in adenocarcinoma, in females, and non-smoking patients.
|
16503085 |
2006 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
|
16510849 |
2006 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
|
16764754 |
2006 |